Navigation

Acuvail

  • Generic Name: ketorolac tromethamine ophthalmic solution
  • Brand Name: Acuvail

Acuvail (Ketorolac Tromethamine Ophthalmic Solution) side effects drug center

 

PROFESSIONAL

CONSUMER

SIDE EFFECTS

 

Acuvail Side Effects Center

What Is Acuvail?

Acuvail (ketorolac tromethamine) Ophthalmic Solution is a nonsteroidal anti-inflammatory drug (NSAID) used to treat pain inflammation after cataract surgery or corneal refractive surgery, and also to relieve eye itching caused by seasonal allergies.

What Are Side Effects of Acuvail?

Common side effects of Acuvail include:

  • mild burning,
  • stinging, or
  • itching of your eyes; swollen or puffy eyelids, or
  • headache

Dosage for Acuvail

The dose of Acuvail is to apply one drop to the affected eye twice daily beginning 1 day prior to cataract surgery, continued on the day of surgery, and through the first 2 weeks of the postoperative period.

What Drugs, Substances, or Supplements Interact with Acuvail?

Acuvail may interact with blood thinners. Tell your doctor all medications and supplements you use.

Acuvail During Pregnancy and Breastfeeding

During pregnancy, Acuvail should be used only if prescribed. It is unknown if this drug passes into breast milk. Consult your doctor before breastfeeding.

Additional Information

Our Acuvail (ketorolac tromethamine) Ophthalmic Solution Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

 

Acuvail Consumer Information

Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have:

  • severe burning, stinging, or itching of your eyes;
  • a wound that will not heal;
  • eye pain, redness, or watering;
  • vision changes, increased sensitivity to light;
  • white patches on your eyes; or
  • crusting or drainage from your eyes.

Common side effects may include:

  • mild eye pain, stinging, or redness;
  • blurred vision;
  • watery eyes;
  • swollen or puffy eyelids; or
  • headache.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Read the entire detailed patient monograph for Acuvail (Ketorolac Tromethamine Ophthalmic Solution)

 

Acuvail Professional Information

SIDE EFFECTS

Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to the rates in the clinical studies of another drug and may not reflect the rates observed in practice.

Clinical Studies Experience

The most common adverse reactions were reported in 1-6% of patients and included increased intraocular pressure, conjunctival hyperemia and/or hemorrhage, corneal edema, ocular pain, headache, tearing and vision blurred. Some of these reactions may be the consequence of the cataract surgical procedure.

Postmarketing Experience

The following adverse reactions have been identified during postmarketing use of ketorolac tromethamine ophthalmic solutions in clinical practice. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. The reactions, which have been chosen for inclusion due to either their seriousness, frequency of reporting, possible causal connection to topical ketorolac tromethamine ophthalmic solutions or a combination of these factors, include bronchospasm, exacerbation of asthma, corneal erosion, corneal perforation, corneal thinning and corneal melt, epithelial breakdown [see WARNINGS AND PRECAUTIONS] and ulcerative keratitis.

Read the entire FDA prescribing information for Acuvail (Ketorolac Tromethamine Ophthalmic Solution)

&Copy; Acuvail Patient Information is supplied by Cerner Multum, Inc. and Acuvail Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.